Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
– Strong early
– Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025
– SKYTROFA® full year 2024 revenue was ~€202 million, excluding sales deductions related to prior years, (€197.0 million plus ~€5 million of sales deductions related to prior years)
– Total 2024 operating expenses of €598 million
– Conference call today at
“Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong revenue growth in 2025 and beyond,” said
Select 2024 Highlights & Anticipated 2025 Milestones
- TransCon hGH
(lonapegsomatropin, marketed as SKYTROFA)- SKYTROFA fourth quarter 2024 revenue excluding a positive impact due to reversal of €4.6 million of sales deductions related to prior years was ~€54 million (fourth quarter reported 2024 SKYTROFA revenue of €58.5 million).
- SKYTROFA full year 2024 revenue excluding €4.7 million of sales deductions related to prior years was ~€202 million (full year reported 2024 SKYTROFA revenue of €197.0 million).
- Prescription Drug User Fee Act (PDUFA) goal date of
July 27, 2025 , for FDA review of supplemental BLA for the treatment of adults with growth hormone deficiency; pending approval,U.S. commercial launch planned in the fourth quarter of 2025. - During the third quarter of 2025, plan to submit an Investigational New Drug (IND) application or similar for a basket trial evaluating TransCon hGH in additional indications.
- TransCon PTH
(palopegteriparatide, marketed as YORVIPATH)- YORVIPATH revenue for the fourth quarter of 2024 totaled €13.6 million and €28.7 million for the full year 2024, as previously announced.
- Strong start to
U.S. YORVIPATH launch, with 908 prescriptions as ofFeb. 7, 2025 , and 539 unique prescribing health care providers. - Expect commercial launch in at least five additional Europe Direct countries in 2025.
- Eight International Markets exclusive distribution agreements signed covering 50+ countries.
- TransCon CNP
(navepegritide)- Following pre-NDA meeting with FDA, on track to submit New Drug Application (NDA) for the treatment of achondroplasia in children during the first quarter of 2025, and to submit Marketing Authorisation Application (MAA) to the
European Medicines Agency during the third quarter of 2025. - Presented new data demonstrating additional benefits beyond linear growth, with significant improvements in leg bowing (a common complication in achondroplasia) observed with TransCon CNP compared to worsening observed with placebo in pivotal ApproaCH Trial.
- During the fourth quarter of 2025, plan to submit an IND or similar for the treatment of hypochondroplasia.
- Following pre-NDA meeting with FDA, on track to submit New Drug Application (NDA) for the treatment of achondroplasia in children during the first quarter of 2025, and to submit Marketing Authorisation Application (MAA) to the
- TransCon hGH / TransCon CNP Combination Treatment
- Topline Week 26 results from Phase 2 COACH Trial (TransCon CNP in combination with TransCon hGH) in children with achondroplasia expected in the second quarter of 2025.
- Oncology Program
- Clinical development of TransCon IL-2 β/γ continues, including ongoing investigation of clinical activity in platinum-resistant ovarian cancer (PROC).
- Financial Update
December 31, 2024 , cash and cash equivalents totaling €559.5 million.- Subsequent to the year end, in
January 2025 , received$100 million related to the Exclusive License Agreement withNovo Nordisk announced last year. Including the$100 million upfront payment, cash at the end of 2024 would have totaled €655 million.
Fourth Quarter and Full Year 2024 Financial Results
Total revenue for the fourth quarter of 2024 was €173.9 million, compared to €137.7 million during the same period for 2023. The increase was primarily attributable to the upfront fee of
Total revenue for 2024 was €363.6 million compared to €266.7 million in 2023. The increase was primarily attributable to the upfront fee of
| Total Revenue (In EUR'000s) |
Three Months Ended |
Twelve Months Ended |
||||||||||
| 2024 |
2023 |
2024 |
2023 |
|||||||||
| Revenue from external customers | ||||||||||||
| Commercial products | 72,130 | 64,249 | 225,728 | 178,663 | ||||||||
| Licenses | 95,853 | 64,304 | 122,343 | 66,077 | ||||||||
| Other | 5,933 | 9,150 | 15,570 | 21,978 | ||||||||
| Total revenue from external customers | 173,916 | 137,703 | 363,641 | 266,718 | ||||||||
| Commercial Product Revenue (In EUR'000s) |
Three Months Ended |
Twelve Months Ended |
||||||||||
| 2024 |
2023 |
2024 |
2023 |
|||||||||
| Revenue from commercial products | ||||||||||||
| SKYTROFA® | 58,546 | 64,249 | 197,001 | 178,663 | ||||||||
| YORVIPATH® | 13,584 | — | 28,727 | — | ||||||||
| Total revenue from commercial products | 72,130 | 64,249 | 225,728 | 178,663 | ||||||||
Research and development (R&D) costs for the fourth quarter of 2024 were €79.3 million, compared to €90.9 million during the same period in 2023. The decline was largely due to lower external development costs for TransCon hGH and TransCon PTH, as well as the Eyconis spin-off. R&D costs for 2024 were €307.0 million compared to €413.5 million in 2023. The lower R&D costs in 2024 was driven primarily by a decrease in external program development costs as well as the Eyconis spin-off.
Selling, general, and administrative (SG&A) expenses for the fourth quarter of 2024 were €80.2 million, compared to €64.0 million during the same period in 2023. The increase was due to higher employee costs, including the impact from global commercial expansion, and higher external commercial costs. SG&A expenses for 2024 were €291.1 million compared to €264.4 million in 2023. Higher SG&A expenses were primarily due to higher employee related expenses and other general and administrative expenses attributable to organizational growth in support of launch of YORVIPATH in
Total operating expenses for the fourth quarter of 2024 were €159.5 million compared to €154.9 million during the same period in 2023. Total operating expenses for 2024 were €598.1 million compared to €677.9 million in 2023.
Net finance expenses were €33.2 million in the fourth quarter compared to €41.6 million in the same period in 2023. Net finance expenses for 2024 were €74.4 million compared to €0.2 million in 2023. The full year net finance expense increase was driven primarily by non-cash items.
For the fourth quarter of 2024,
As of
Conference Call and Webcast Information
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the
About
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the timing of NDA, MAA and IND submissions for TransCon CNP; (ii) Ascendis’ ability to continue strong revenue growth in 2025 and beyond; (iii) YORVIPATH’s ability to become the new global standard for the treatment of hypoparathyroidism in adults; (iv) Ascendis’ ability to become a leading global biopharmaceutical company with multiple blockbuster products and a strong engine for future innovation; (v) the PDUFA goal date for FDA review of SKYTROFA’s supplemental BLA for the treatment of adults with growth hormone deficiency and Ascendis’ plans for a
Ascendis,
©
| Investor Contacts: | Media Contact: |
| ir@ascendispharma.com | +1 (650) 709-8875 |
| media@ascendispharma.com | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
NEW AND AMENDED IFRS ACCOUTING STANDARDS AND INTERPRETATIONS
The Company has applied amendments to paragraphs 69 to 76 of IAS 1, “Presentation of Financial Statements,” which was effective for annual reporting periods beginning on or after
FINANCIAL TABLES FOLLOW
Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (In EUR'000s, except share and per share data) |
Three Months Ended |
Twelve Months Ended |
||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Consolidated Statement of Profit or (Loss) | ||||||||||||
| Revenue | 173,916 | 137,703 | 363,641 | 266,718 | ||||||||
| Cost of sales | 14,023 | 19,457 | 44,258 | 44,395 | ||||||||
| Gross profit | 159,893 | 118,246 | 319,383 | 222,323 | ||||||||
| Research and development costs | 79,294 | 90,881 | 307,004 | 413,454 | ||||||||
| Selling, general, and administrative expenses | 80,216 | 63,975 | 291,142 | 264,410 | ||||||||
| Operating profit/(loss) | 383 | (36,610 | ) | (278,763 | ) | (455,541 | ) | |||||
| Share of profit/(loss) of associates | (4,575 | ) | (2,924 | ) | (20,060 | ) | (18,395 | ) | ||||
| Finance income | 26,233 | 22,727 | 25,609 | 43,857 | ||||||||
| Finance expenses | 59,425 | 64,280 | 100,027 | 44,065 | ||||||||
| Profit/(loss) before tax | (37,384 | ) | (81,087 | ) | (373,241 | ) | (474,144 | ) | ||||
| Income taxes (expenses) | (1,085 | ) | (5,791 | ) | (4,843 | ) | (7,303 | ) | ||||
| Net profit/(loss) for the period | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Attributable to owners of the Company | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Basic and diluted earnings/(loss) per share | € (0.64 | ) | € (1.54 | ) | € (6.53 | ) | € (8.55 | ) | ||||
| Number of shares used for calculation (basic and diluted) | 59,785,166 | 56,560,368 | 57,891,570 | 56,287,060 | ||||||||
| Consolidated Statement of Comprehensive Income or (Loss) | ||||||||||||
| Net profit/(loss) for the period | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Other comprehensive income/(loss) | ||||||||||||
| Items that may be reclassified subsequently to profit or (loss): | ||||||||||||
| Exchange differences on translating foreign operations | 830 | (1,498 | ) | 1,062 | (2,731 | ) | ||||||
| Other comprehensive income/(loss) for the period, net of tax | 830 | (1,498 | ) | 1,062 | (2,731 | ) | ||||||
| Total comprehensive income/(loss) for the period, net of tax | (37,639 | ) | (88,376 | ) | (377,022 | ) | (484,178 | ) | ||||
| Attributable to owners of the Company | (37,639 | ) | (88,376 | ) | (377,022 | ) | (484,178 | ) | ||||
Consolidated Statements of Financial Position (In EUR'000s) |
|||||||||
| Assets | |||||||||
| Non-current assets | |||||||||
| Intangible assets | 4,028 | 4,419 | 4,828 | ||||||
| Property, plant and equipment | 98,714 | 110,634 | 129,095 | ||||||
| Investments in associates | 13,575 | 5,686 | 22,932 | ||||||
| Other receivables | 2,317 | 2,127 | 1,920 | ||||||
| Marketable securities | — | — | 7,492 | ||||||
| 118,634 | 122,866 | 166,267 | |||||||
| Current assets | |||||||||
| Inventories | 295,609 | 208,931 | 130,673 | ||||||
| Trade receivables | 166,280 | 35,874 | 11,910 | ||||||
| Income tax receivables | 1,775 | 802 | 883 | ||||||
| Other receivables | 9,385 | 19,097 | 12,833 | ||||||
| Prepayments | 28,269 | 38,578 | 31,717 | ||||||
| Marketable securities | — | 7,275 | 290,688 | ||||||
| Cash and cash equivalents | 559,543 | 392,164 | 444,767 | ||||||
| 1,060,861 | 702,721 | 923,471 | |||||||
| Total assets | 1,179,495 | 825,587 | 1,089,738 | ||||||
| Equity and liabilities | |||||||||
| Equity | |||||||||
| Share capital | 8,149 | 7,749 | 7,675 | ||||||
| Distributable equity | (113,855 | ) | (153,446 | ) | 255,673 | ||||
| Total equity | (105,706 | ) | (145,697 | ) | 263,348 | ||||
| Non-current liabilities | |||||||||
| Borrowings | 365,080 | 222,996 | 95,400 | ||||||
| Contract liabilities | 5,000 | 5,949 | 14,213 | ||||||
| Deferred tax liabilities | 7,258 | 5,830 | — | ||||||
| 377,338 | 234,775 | 109,613 | |||||||
| Current liabilities | |||||||||
| Convertible notes, matures in |
|||||||||
| Borrowings | 458,207 | 407,095 | 399,186 | ||||||
| Derivative liabilities | 150,670 | 143,296 | 157,950 | ||||||
| 608,877 | 550,391 | 557,136 | |||||||
| Other current liabilities | |||||||||
| Borrowings | 33,329 | 14,174 | 13,791 | ||||||
| Contract liabilities | 936 | 1,184 | — | ||||||
| Trade payables and accrued expenses | 96,394 | 94,566 | 101,032 | ||||||
| Other liabilities | 67,956 | 41,176 | 31,989 | ||||||
| Income tax payables | 1,222 | 2,299 | 5,490 | ||||||
| Provisions | 99,149 | 32,719 | 7,339 | ||||||
| 298,986 | 186,118 | 159,641 | |||||||
| 907,863 | 736,509 | 716,777 | |||||||
| Total liabilities | 1,285,201 | 971,284 | 826,390 | ||||||
| Total equity and liabilities | 1,179,495 | 825,587 | 1,089,738 | ||||||
| *Restatement relates to adoption of amendments to IAS 1 “Presentation of Financial Statements.” | |||||||||
| Refer to Note 2 in the financial statements of Ascendis’ Annual Report on Form 20-F for further details. | |||||||||
Source: Ascendis Pharma